info@p-95.com

proposal request

Clinical Trial Delivery

Comprehensive Clinical Trial Support for Vaccines and Infectious Disease.

Data, Analysis and writing

Our data management, biostatistics, safety management and medical writing teams ensure data integrity and insightful analysis for vaccines and drugs across all stages of development.

Epidemiology and Real-World Evidence (RWE) Solutions

Comprehensive Epidemiology and RWE solutions for Vaccines and Infectious Diseases.

Africa and LMICs

Expanding Clinical and Epidemiological Horizons: Expertise in Africa, LMICs, and Beyond.

VIEW ALL SERVICES

All News

Read Article

Read Article

News

P95 welcomes John O’Brien as Chief Business Officer

By P95

March 6, 2024
We are excited to welcome John O’Brien as our new Chief Business Officer! John has a proven track record of driving commercial success and building strategic partnerships, bringing a wealth of experience to our team.

“I am delighted to welcome John to our team! His visionary leadership and innovative approach will be instrumental in driving our company forward as we continue our jounrey to be the premier provider of clinical and epidemiological services for vaccine developers worldwide.” – Thomas Verstraeten, P95 Chief Executive Officer

John joins us from his previous role as Chief Commercial Officer at Excelya Group, a contract research organization (CRO) providing full-service clinical, FSP, and resourcing solutions. Prior to this, John held leadership and business development roles in various clinical CROs including Cmed, Chiltern, Theorem Clinical and Parexel.

Please join us in extending a warm welcome to John! We are excited to have him on board and look forward to his valuable contributions to our organization’s continued success.

Stay tuned for exciting updates as we embark on this new chapter together!

P95

Pioneering Clinical Excellence in Vaccines and Infectious Diseases

Tags:

0 Comments

You May Also Like

P95’s Journey From Epidemiology Consulting to Comprehensive CRO

P95’s Journey From Epidemiology Consulting to Comprehensive CRO

Apr 12 |

In a recent interview for Ampersand Capital Partners, our CEO, Thomas Verstraeten, and Chairman, Benoit Bouche shared pivotal insights into P95’s growth from an epidemiology consulting into a global comprehensive Contract Research Organization (CRO).

Almost one year from P95’s partnership with Ampersand Capital Partners, the article dives deeper into P95’s expanding global reach, client-focused capabilities, and commitment to global health that bring our company to the forefront.